{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:12:30Z","timestamp":1789135950294,"version":"build-2803163510"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The FDA-approved package insert for aripiprazole lauroxil (AL) indicates that the 1064-mg dose should be administered as an intramuscular injection in the gluteal muscle every 8 weeks. Administration at different sites may change how the drug is absorbed and eliminated, thereby altering the peak medication level, half-life, and time to next injection. Currently, there is a dearth of published reports that describe the pharmacokinetics of this dose when administered at an injection site other than the gluteal muscle.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A patient inadvertently received the first injection of AL 1064 mg in the deltoid muscle. Given the absence of pharmacokinetic data for this administration site, serial serum aripiprazole concentrations were obtained to assist in determining the best course of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Intradeltoid administration was associated with a higher observed maximum concentration (C\n                      <jats:sub>max<\/jats:sub>\n                      ), a similar time to reach C\n                      <jats:sub>max<\/jats:sub>\n                      (t\n                      <jats:sub>max<\/jats:sub>\n                      ), and prolonged exposure. Confounding variables may have affected the data. Based on the medication levels, the next injection was delayed until 13 weeks after the initial injection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This case report is the first to describe how the pharmacokinetics of AL 1064 mg are altered when inadvertently administered in the deltoid muscle.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001475","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:00:08Z","timestamp":1778108408000},"page":"559-561","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Serum Aripiprazole Concentrations After Inadvertent Intradeltoid Administration of Aripiprazole Lauroxil 1064 mg: A Case Report"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2167-1121","authenticated-orcid":false,"given":"Erica A. K.","family":"Davis","sequence":"first","affiliation":[{"name":"Department of Practice, Sciences, and Health Outcomes Research (P-SHOR), University of Maryland, Baltimore School of Pharmacy, Baltimore, Maryland"},{"name":"Springfield Hospital Center, Sykesville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mollenhauer","sequence":"additional","affiliation":[{"name":"Springfield Hospital Center, Sykesville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpt197517144","article-title":"Blood flow in muscle groups and drug absorption","volume":"17","author":"Evans","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.pnpbp.2009.05.014","article-title":"Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia","volume":"33","author":"Hough","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/jcph.295","article-title":"A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia","volume":"54","author":"Cleton","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.schres.2014.09.021","article-title":"Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia","volume":"159","author":"Turncliff","year":"2014","journal-title":"Schizophr Res"},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40263-017-0447-7","article-title":"Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase I study and a population pharmacokinetic model","volume":"31","author":"Hard","year":"2017","journal-title":"CNS Drugs"},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40263-020-00745-1","article-title":"Pharmacokinetics, safety, and tolerability of a 2-month dose interval regimen of the long-acting injectable antipsychotic aripiprazole lauroxil: results from a 44-week phase I study","volume":"34","author":"Weiden","year":"2020","journal-title":"CNS Drugs"},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0000000000000691","article-title":"Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia","volume":"37","author":"Hard","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.forsciint.2013.03.021","article-title":"Stability of some atypical antipsychotics in human plasma, haemolysed whole blood, oral fluid, human serum and calf serum","volume":"229","author":"Fisher","year":"2013","journal-title":"Forensic Sci Int"},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.forsciint.2011.02.022","article-title":"Assessment of the stability of 30 antipsychotic drugs in stored blood specimens","volume":"215","author":"Saar","year":"2012","journal-title":"Forensic Sci Int"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1007\/s00213-022-06233-2","article-title":"Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis","volume":"239","author":"Hart","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/FTD.0b013e318178e18d","article-title":"Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia","volume":"30","author":"Bachmann","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R14-20260911","first-page":"59","article-title":"Review of grapefruit juice\u2013drugs interactions mediated by intestinal CYP3A4 inhibition","volume":"14","author":"Dayyih","year":"2024","journal-title":"J Appl Pharm Sci"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:00:36Z","timestamp":1789135236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001475","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"2026-01-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}